Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 9:4:7394.
doi: 10.1038/srep07394.

Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis

Affiliations

Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis

Jun Wang et al. Sci Rep. .

Abstract

Patients with schizophrenia have a higher risk for cardiovascular disease (CVD) than the general population. Research has suggested that autonomic imbalance is a common pathway to increased morbidity and mortality for CVD. Heart rate variability (HRV) analysis is a non-invasive method that assesses autonomic imbalance, and low HRV is correlated with high cardiovascular risk. Olanzapine, a widely used antipsychotic drug, is considered to have good cardiac safety because of not causing significant corrected QT-interval (QTc) prolongation; however, it is still unclear whether olanzapine affects HRV. We recruited 83 patients with schizophrenia who were medication-free for at least 1 month and tested their HRV at the baseline and 4 weeks after treatment with olanzapine. We found that patients who had substantial weight gain (EWG) manifested significantly lower HRV than those who had non-substantial weight gain (NWG) and that HRV decrease was positively correlated to an increase in body mass index (BMI) and weight gain. Our results indicate that olanzapine-induced weight gain may play an important role in its potential cardiovascular risk. Since olanzapine has a very high potential for weight gain compared with other antipsychotics, further research is needed to explore its cardiovascular safety profile, specifically long-term cardiac safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Correlations among changes in body mass index and HRV measurements for the SCZ, EWG and NWG groups.
The change in body mass index (ΔBMI) is positively correlated with the change in the normalized low frequency power LFn (ΔLFn) and the LF/HF ratio (ΔLF/HF) and negatively correlated with the change in the standard deviation for the NN interval (ΔSDNN) and normalized high frequency power (ΔHFn) in both the SCZ and EWG groups (All P < 0.05). There is only a marginal negative correlation between ΔBMI and ΔHFn (P = 0.05) for the NWG group.

Similar articles

Cited by

References

    1. Brown S., Kim M., Mitchell C. & Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196, 116–121 (2010). - PMC - PubMed
    1. Healy D. et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875–1924 and 1994–2010. BMJ Open 2, e001810 (2012). - PMC - PubMed
    1. Koponen H. et al. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 62, 342–345 (2008). - PubMed
    1. Ifteni P., Correll C. U., Burtea V., Kane J. M. & Manu P. Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res 155, 72–76 (2014). - PubMed
    1. Lin S. T. et al. Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. Circulation 130, 235–243 (2014). - PubMed

MeSH terms

LinkOut - more resources